News
STTK
9.58
-5.43%
-0.55
Weekly Report: what happened at STTK last week (0408-0412)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
TipRanks · 04/12 11:00
Analysts Conflicted on These Healthcare Names: Shattuck Labs (STTK), Johnson & Johnson (JNJ) and Tilray (TLRY)
TipRanks · 04/10 16:10
Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
Benzinga · 04/09 20:15
SHATTUCK LABS ANNOUNCES ORAL PRESENTATION OF PRECLINICAL DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2024
Reuters · 04/09 20:05
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Barchart · 04/09 15:05
Shattuck Labs Price Target Maintained With a $12.00/Share by Needham
Dow Jones · 04/09 10:27
Strong Buy Rating for Shattuck Labs on Innovative Immunotherapy Pipeline and Leadership
TipRanks · 04/09 10:16
Weekly Report: what happened at STTK last week (0401-0405)?
Weekly Report · 04/08 09:11
SHATTUCK LABS INC <STTK.O>: CITIGROUP RAISES TARGET PRICE TO $11 FROM $10
Reuters · 04/04 10:15
Weekly Report: what happened at STTK last week (0325-0329)?
Weekly Report · 04/01 09:11
Weekly Report: what happened at STTK last week (0318-0322)?
Weekly Report · 03/25 09:11
Institutional investors control 36% of Shattuck Labs, Inc. (NASDAQ:STTK) and were rewarded last week after stock increased 13%
Institutional investors own 36% of Shattuck Labs, Inc. (NASDAQ:STTK) The company is owned by institutions and the top 7% of the company's shares are held by these institutions. More than half of the business is held by the top seven shareholders. Shattucks Labs has a US$450m market cap. Our analysis shows that the company is well-liked by institutional investors. But the company could be vulnerable to insider selling, and there are six warning signs. We look at the insider ownership of Sh Hattuck Labs and other companies.
Simply Wall St · 03/22 11:01
Weekly Report: what happened at STTK last week (0311-0315)?
Weekly Report · 03/18 09:11
Weekly Report: what happened at STTK last week (0304-0308)?
Weekly Report · 03/11 09:11
Shattuck Labs, Inc.: Report of proposed sale of securities
Press release · 03/06 22:32
Shattuck Labs, Inc.: Current report
Press release · 03/04 16:06
Shattuck Labs Boosts Board with Biotech Heavyweights
TipRanks · 03/04 12:33
Press Release: Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.-D., to its Board of Directors. Shattuck is pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Dr. Siegall was the founder of Seattle Genetics.
Dow Jones · 03/04 12:00
Weekly Report: what happened at STTK last week (0226-0301)?
Weekly Report · 03/04 09:11
More
Webull provides a variety of real-time STTK stock news. You can receive the latest news about Shattuck Labs, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About STTK
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.